Swisschems
Has Swisschems received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Swisschems a warning letter naming semaglutide and retatrutide, dated Dec 10, 2024, with the FDA subject line “Unapproved New Drugs/Misbranded.”
FDA records in this index name Swisschems on Dec 10, 2024.
- Type named in FDA records
- Not stated
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide, Retatrutide
- Latest record
- Dec 10, 2024
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Dec 10, 2024 | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Dec 10, 2024: … in October 2024 and has observed that your website offers “ Semaglutide ” and “Retatrutide” products for sale in the … to purchase your products. As described below, your “ Semaglutide ” and “Retatrutide” products are unapproved new … use include, but may not be limited to, the following: Semaglutide On the product webpage for “ Semaglutide ,” … Full letter
Drug recalls
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.